Document:

exv4waw8

Exhibit 4(a)(8)

CORPORATE INTEGRITY AGREEMENT

BETWEEN THE

OFFICE OF INSPECTOR GENERAL

OF THE

DEPARTMENT OF HEALTH AND HUMAN SERVICES

AND

ELAN CORPORATION, PLC

I. Preamble

     Elan Corporation, plc hereby enters into this Corporate Integrity Agreement (CIA) with the
Office of Inspector General (OIG) of the United States Department of Health and Human Services
(HHS) to promote compliance with the statutes, regulations, and written directives of Medicare,
Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f))
(Federal health care program requirements) and with the statutes, regulations, and written
directives of the Food and Drug Administration (FDA requirements). This CIA specifically applies to
Elan Corporation, plc and all its corporate subsidiaries, or other Elan affiliates (as defined
below) that engage or employ individuals who meet the definition of Covered Persons set forth below
in Section II (collectively “Elan”). Contemporaneously with this CIA, Elan Corporation, plc is
entering into a Settlement Agreement with the United States. Elan Corporation, plc will also enter
into settlement agreements with various States (Medicaid State Settlement Agreements), and Elan
Corporation, plc’s agreement to this CIA is a condition precedent to those agreements.

     Prior to the Effective Date, Elan established a compliance program and initiated certain
voluntary compliance measures designed to address its U.S. health care operations and compliance
with Federal health care program and FDA requirements. Elan shall continue its compliance program
through the term of the CIA and shall do so as set forth below. Elan may modify its compliance
program as appropriate, but at a minimum Elan shall ensure that during the term of the CIA, it
shall comply with the obligations set forth herein.

     Elan represents that as of the Effective Date of this CIA (as defined below in Section II.A)
with limited exceptions and except as otherwise described to OIG, its employees currently do not
engage in Promotion Related Functions (as defined below in Section II.C.6) in the United States.
Rather, Elan is primarily a research and development company that currently provides limited
support for (not through the use of a field sales force) and distributes one Government Reimbursed
Product (as defined below in Section II.C.3). If during the term of this CIA, Elan intends to
engage in additional Promotion Related Functions in the United States, Elan shall notify the OIG,
in writing, of that intention 120 days prior to commencing such Promotion Related Functions or as
soon as practical subject to any other confidentiality requirements. Elan further agrees that, if
Elan intends to engage in additional Promotion Related Functions (either through contractors or
employees of Elan) (i.e., field based personnel employed or contracted by Elan to promote Elan
Government Reimbursed Products), the OIG will amend and expand the requirements of this CIA to
address the additional marketing and promotional operations of Elan in the United States. Elan
agrees to provide information to the OIG about the additional intended Promotion Related Functions
as necessary for the OIG to appropriately amend the CIA. Elan agrees that it shall not engage in
additional Promotion Related Functions in the United States, including by re-instituting or
re-establishing a sales force, until after it enters an amended CIA

1

 

that includes provisions acceptable to the OIG that address such additional promotional
activities. The amended CIA would likely be modified, at a minimum, to expand the definition of
Covered Persons (Section II.C.1) and Relevant Covered Persons (Section II.C.2), to require
additional policies and procedures, training requirements, and monitoring requirements relating to
the additional operations of Elan. The amended CIA may also require that the Audit Committee (as
defined below in Section III.A.3) retain a Compliance Expert to conduct a review of Elan’s
Compliance Program.

     The provisions of the amended CIA shall be determined at the sole discretion of the OIG after
considering, among other things, information and documentation provided by Elan.

II. Term and Scope of the CIA

     A. The period of the compliance obligations assumed by Elan under this CIA shall be 5 years
from the Effective Date of this CIA, unless otherwise specified. The Effective Date shall be the
date on which the final signatory of this CIA executes this CIA (Effective Date). Each one-year
period, beginning with the one-year period following the Effective Date, shall be referred to as a
“Reporting Period.”

     B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1)
Elan’s final Annual Report; or (2) any additional materials submitted by Elan pursuant to OIG’s
request, whichever is later.

     C. The scope of this CIA shall be governed by the following definitions:

     1. “Covered Persons” includes:

a. all owners who are natural persons (other than shareholders who: (1) have
an ownership interest of less than 5% and (2) acquired the ownership interest
through public trading) and all officers of Elan Corporation, plc, and all
Elan Affiliates (as defined below);

b. all directors of Elan and all Elan Affiliates;

c. all employees of Elan and any Elan Affiliate who are: 1) based in the
United States; or 2) based outside the United States and who have
responsibilities relating to Government Pricing and Contracting Function,
Medical Affairs and Materials Related Functions, or (if applicable in the
future) Promotion Related Functions; and

d. all contractors, subcontractors, agents, and other persons who perform
Government Pricing and Contracting Functions, Medical Affairs and Materials
Related Functions, or (if applicable in the future) Promotion Related
Functions on behalf of Elan or any Elan Affiliate.

Notwithstanding the above, the term “Covered Persons” does not include: (i)
officers, employees, contractors, subcontractors, agents, of the Elan Drug
Technologies line of business; (ii) employees, contractors, subcontractors, agents

-2-

 

or other personnel of Elan, or any Elan Affiliate, who perform only manufacturing
functions, so long as such personnel do not have responsibilities relating to
Government Pricing and Contracting Functions, Medical Affairs and Materials Related
Functions, or (if applicable in the future) Promotion Related Functions; and (iii)
part-time or per diem employees, contractors, subcontractors, agents, and other
persons who are not reasonably expected to work more than 160 hours per year, except
that any such individuals shall become “Covered Persons” at the point when they work
more than 160 hours during the calendar year.

     2. “Relevant Covered Persons” includes all Covered Persons whose job responsibilities
relate to Government Pricing and Contracting Functions, Medical Affairs and Materials
Related Functions, or (if applicable in the future) Promotion Related Functions as defined
below in Sections II.C.4-6, respectively.

     3. “Government Reimbursed Products” refers to all Elan pharmaceutical or biological
products that are promoted or sold by Elan in the United States and reimbursed by Federal
health care programs. This term includes all products promoted or sold by Elan or Elan
Affiliates.

     4. The term “Government Pricing and Contracting Functions” means the collection,
calculation, verification, or reporting of pricing and other information for purposes of the
Medicaid Drug Rebate Program (codified at 42 U.S.C. § 1396r-8, et seq.), the Medicare
Program (codified at 42 U.S.C. § 1395-1395hhh), the 340B Drug Pricing Program (codified at
42 U.S.C. § 256(b)), or any other government programs through which health care items or
services may be purchased or reimbursed, in whole or in part, by the federal government, and
the Veteran’s Administration pricing program (the “VA Programs”), as set forth in the
Federal Supply Schedule and the Veteran’s Healthcare Act of 1992. This definition includes,
but is not limited to, the calculation and reporting of Average Sales Price (ASP), Average
Manufacturer Price (AMP), Best Price (BP), and all pricing and other information reported
and used in connection with reimbursement under the health care programs described in this
paragraph.

     5. The term “Medical Affairs and Materials Related Functions” means the field and
headquarters functions associated with (i) providing responses to medical inquiries by
health care providers (HCPs); (ii) the functions of Elan’s Clinical Science Liaisons (CSLs);
(iii) contracting with HCPs in the United States to conduct post-marketing clinical trials
and post-marketing studies relating to Government Reimbursed Products; (iv) authorship,
publication, and disclosure of articles or study results relating to Government Reimbursed
Products; (v) the preparation or external dissemination of promotional or medical
information materials about Government Reimbursed Products in the United States by Elan,
including those functions relating to any applicable review committees and to Elan’s Medical
Affairs Department (Medical Affairs); and (vi) the provision of services relating to
Government Reimbursed Products.

     6. The term “Promotion Related Functions” includes the promotion, detailing, marketing,
branding, and/or advertising of Government Reimbursed Products, including but not limited
to, through a field sales force.

-3-

 

     7. The term “Elan Affiliate” shall mean any entity that is owned or controlled,
directly or indirectly, by Elan Corporation, plc, including, but not limited to Elan
Pharmaceuticals, Inc., Elan Pharma International Limited, and Elan Drug Delivery, Inc., and
whose employees or contractors perform Government Pricing and Contracting Functions, Medical
Affairs and Materials Related Functions, or (if applicable in the future) Promotion Related
Functions.

     8. The term “Third Party Personnel” shall mean personnel who perform Government Pricing
and Contracting Functions, Medical Affairs and Materials Related Functions, or Promotion
Related Functions who are employees of entities with whom Elan or any Elan Affiliate has or
may in the future (during the term of this CIA) enter into collaboration agreements or
agreements to co-promote or co-develop a Government Reimbursed Product in the United States.
Elan has represented that: 1) Third Party Personnel are employed by entities other than Elan
or any Elan Affiliate; 2) neither Elan nor any Elan Affiliate controls the Third Party
Personnel; and (3) it would be commercially impracticable to compel the compliance of Third
Party Personnel with the requirements set forth in this CIA. Elan agrees that Elan and Elan
Affiliates shall promote compliance by Third Party Personnel with Federal health care
program and FDA requirements by complying with the provisions set forth below in Sections
III.B.2, V.A.7 and V.B.5. Provided that Elan complies with the requirements of Sections
III.B.2, V.A.7 and V.B.5, Elan shall not be required to fulfill the other CIA obligations
that would otherwise apply to Third Party Personnel who meet the definition of Covered
Persons.

III. Corporate Integrity Obligations

          Elan shall establish and maintain a Compliance Program that includes the following elements:

          A. Chief Compliance Officer and Committee.

          1. Chief Compliance Officer. Prior to the Effective Date, Elan Corporation, plc appointed an
individual to serve as its Chief Compliance Officer. During the term of this CIA, the Chief
Compliance Officer shall continue to be authorized to oversee compliance with regard to Elan’s U.S.
operations, with Federal health care program requirements and FDA requirements, and with the
requirements of this CIA. Elan shall maintain a Chief Compliance Officer during the term of the
CIA. The Chief Compliance Officer shall be responsible for developing and implementing policies,
procedures, and practices designed to ensure compliance with the requirements set forth in this CIA
and with Federal health care program and FDA requirements. The Chief Compliance Officer shall be a
member of senior management of Elan, shall report directly to the Chief Executive Officer of Elan,
shall make periodic (at least quarterly) reports regarding compliance matters directly to the Audit
Committee of the Board of Directors of Elan Corporation, plc, and shall be authorized to report on
such matters to the Audit Committee at any time. The Chief Compliance Officer shall not be or be
subordinate to the Elan Corporation, plc General Counsel or Chief Financial Officer. The Chief
Compliance Officer shall be responsible for monitoring the day-to-day compliance activities engaged
in by Elan as well as for any reporting obligations created under this CIA. Any noncompliance job
responsibilities of the Chief Compliance Officer

-4-

 

shall be limited and must not interfere with the Chief Compliance Officer’s ability to perform
the duties outlined in this CIA.

     Elan shall report to OIG, in writing, any changes in the identity or position description of
the Chief Compliance Officer, or any actions or changes that would affect the Chief Compliance
Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within 5
days after such a change.

     2. Compliance Committee. Prior to the Effective Date, Elan established a Compliance Committee
and Elan shall maintain a Compliance Committee during the term of this CIA. The Compliance
Committee shall, at a minimum, include the Chief Compliance Officer and other members of senior
management necessary to meet the requirements of this CIA (e.g., senior executives of
relevant departments, such as regulatory, government contracting, human resources, audit,
operations, legal, medical affairs, and (if applicable) sales and marketing). The Chief Compliance
Officer shall chair the Compliance Committee and the Committee shall support the Chief Compliance
Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of the
organization’s risk areas and shall oversee monitoring of internal and external audits and
investigations). The Compliance Committee shall meet at least quarterly.

     Elan shall report to OIG, in writing, any changes in the composition of the Compliance
Committee, or any actions or changes that would affect the Compliance Committee’s ability to
perform the duties necessary to meet the obligations in this CIA, within 5 days after such a
change.

     3. Audit Committee Compliance Obligations. The Audit Committee of the Board of Directors of
Elan Corporation, plc, (Audit Committee) shall be responsible for the review and oversight of
matters related to compliance with Federal health care program requirements, FDA requirements, and
the obligations of this CIA. The Audit Committee shall, at a minimum, be responsible for the
following:

     a. The Audit Committee shall meet at least quarterly to review and oversee Elan’s Compliance
Program, including but not limited to the performance and activities of the Chief Compliance
Officer and compliance personnel who are “Covered Persons” under this CIA.

     b. For each Reporting Period of the CIA, the Audit Committee shall adopt a resolution, signed
by each individual member of the Audit Committee, summarizing its review and oversight of Elan’s
compliance with Federal health care program requirements, FDA requirements, and the obligations of
this CIA.

     At minimum, the resolution shall include the following language:

     “The Audit Committee of the Board of Directors has made a reasonable inquiry into the
operations of Elan’s Compliance Program, including the performance of the Chief Compliance Officer
and the compliance personnel who are “Covered Persons” under this CIA. Based on its inquiry, the
Audit Committee has concluded that, to the best of its knowledge, Elan has implemented an effective
Compliance Program to meet Federal health care program requirements, FDA requirements, and the
obligations of the CIA.”

-5-

 

     If the Audit Committee is unable to provide such a conclusion in the resolution, the Audit
Committee shall include in the resolution a written explanation of the reasons why it is unable to
provide the conclusion and the steps it is taking to implement an effective Compliance Program at
Elan.

     Elan shall report to OIG, in writing, any changes in the composition of the Audit Committee of
the Board, or any actions or changes that would affect the Committee’s ability to perform the
duties necessary to meet the obligations in this CIA, within 15 days after such a change.

     4. Management Accountability and Certifications: In addition to the responsibilities set forth
in this CIA for all Covered Persons, certain Elan officers or employees (“Certifying Employees”)
are specifically expected to monitor and oversee activities within their areas of authority and
shall annually certify that the applicable Elan business unit is compliant with applicable Federal
health care program and FDA requirements, and with the obligations of this CIA. These Certifying
Employees shall include, at a minimum, the following: the Chief Executive Officer of Elan
Corporation, plc, the President of Elan Corporation plc, and all appropriate Elan executives,
vice-presidents, and directors as would be necessary to ensure that there is a certifying officer
or executive-level employee with management responsibility for each of the following functions:
Medical Affairs and Materials Related Functions, Government Pricing and Contracting Related
Functions, and (if applicable in the future) Promotion Related Functions.

     For each Reporting Period, each Certifying Employee shall sign a certification that states:

     “I have been trained on and understand the compliance requirements and responsibilities as
they relate to [department or functional area], an area under my supervision. My job
responsibilities include ensuring compliance with regard to the______ [insert name of the
department or functional area] with all applicable Federal health care program requirements, FDA
requirements, obligations of the Corporate Integrity In the event that I have identified potential
issues of noncompliance with these requirements, I have referred all such issues to the Compliance
Department for further review and follow-up in accordance with Elan’s policies and procedures.
Apart from those referred issues, I am not currently aware of any violation of applicable Federal
health care program requirements, FDA requirements, and the requirements of the Corporate Integrity
Agreement, or the requirements of Elan’s policies. I understand that this certification is being
provided to and relied upon by the United States.”

     If any Certifying Employee is unable to provide such a conclusion in the certification, the
Certifying Employee shall provide a written explanation of the reasons why he or she is unable to
provide the certification outlined above and the steps being taken to address the issue(s)
identified in the certification.

     B. Written Standards.

     1. Code of Conduct. Prior to Effective Date, Elan developed, implemented, and
distributed written a Code of Conduct to all Covered Persons. Elan shall make the

-6-

 

promotion of, and adherence to, the Code of Conduct an element in evaluating the
performance of all employees.

     The Code of Conduct shall, at a minimum, set forth:

a. Elan’s commitment to full compliance with all Federal health care program
and FDA requirements, including its commitment to market, sell, promote,
research, develop, provide information about, and advertise its products in
the U.S. in accordance with Federal health care program and FDA
requirements;

b. Elan’s requirement that all of its Covered Persons shall be expected to
comply with all Federal health care program and FDA requirements and with
Elan’s own Policies and Procedures as implemented pursuant to Section III.B
(including the requirements of this CIA);

c. the requirement that all of Elan’s Covered Persons shall be expected to
report to the Chief Compliance Officer, or other appropriate individual
designated by Elan, suspected violations of any Federal health care program
or FDA requirements or of Elan’s own Policies and Procedures; and

d. the right of all individuals to use the Disclosure Program described in
Section III.E, and Elan’s commitment to nonretaliation and to maintain, as
appropriate, confidentiality and anonymity with respect to such disclosures.

     Within 120 days after the Effective Date, each Covered Person shall certify, in writing, that
he or she has received, read, understood, and shall abide by Elan’s Code of Conduct. New Covered
Persons shall receive the Code of Conduct and shall complete the required certification within 30
days after becoming a Covered Person or within 120 days after the Effective Date, whichever is
later.

     Elan shall periodically review the Code of Conduct to determine if revisions are appropriate
and shall make any necessary revisions based on such review. Any revised Code of Conduct shall be
distributed within 30 days after any revisions are finalized. Each Covered Person shall certify, in
writing, that he or she has received, read, understood, and shall abide by the revised Code of
Conduct within 30 days after the distribution of the revised Code of Conduct.

     2. Third Party Personnel. Within 120 days after the Effective Date, and annually
thereafter by the anniversary of the Effective Date, Elan and/or the appropriate Elan
Affiliate shall send a letter to each entity employing Third Party Personnel. The letter
shall outline Elan’s obligations under the CIA and its commitment to full compliance with
all Federal health care program and FDA requirements. The letter shall include a description
of Elan’s Compliance Program. Elan and/or the Elan Affiliate shall attach a copy of the Code
of Conduct to the letter and shall request the entity employing Third

-7-

 

Party Personnel to either: (a) make a copy of Elan’s Code of Conduct and a description
of Elan’s Compliance Program available to its Third Party Personnel; or (b) represent to
Elan and/or the Elan Affiliate that it has and enforces a substantially comparable code of
conduct and compliance program for its Third Party Personnel.

     3. Policies and Procedures. Within 90 days after the Effective Date, Elan shall
implement written Policies and Procedures regarding the operation of Elan’s compliance
program and its compliance with Federal health care program and FDA requirements. At a
minimum, the Policies and Procedures shall address:

a. the subjects relating to the Code of Conduct identified in Section
III.B.1;

b. appropriate ways to conduct Government Pricing and Contracting Functions
in compliance with all applicable Federal healthcare program and FDA
requirements, including, but not limited to the Federal anti-kickback
statute (codified at 42 U.S.C. § 1320a-7b), and the False Claims Act
(codified at 31 U.S.C. 3729-3733);

c. appropriate ways to conduct Medical Affairs and Materials Related
Functions in compliance with all applicable FDA requirements and Federal
healthcare program requirements, including, but not limited to the Federal
anti-kickback statute (codified at 42 U.S.C. § 1320a-7b), and the False
Claims Act (codified at 31 U.S.C. 3729-3733);

d. the materials and information about Government Reimbursed Products that
may be distributed by Elan personnel, including Medical Affairs personnel
and CSLs, and the mechanisms through, and manner in which, Elan personnel
receive and respond to requests for information about Elan’s Government
Reimbursed Products including the approved and non-FDA approved (or
“off-label”) uses of the products; the form and content of information
disseminated by Elan in response to such requests; and the internal review
process for the information disseminated. These Policies and Procedures
shall require that Elan personnel refer all requests for information about
non-FDA approved (“off-label”) uses of Government Reimbursed Products to the
appropriate Medical Affairs personnel. These Policies and Procedures shall
require that distribution of any reprints of medical journal articles be
consistent with applicable FDA requirements;

The Policies and Procedures shall also require that Medical Affairs develop
a database (“Inquiries Database”) to track all requests for information
about Elan’s products to Medical Affairs. The Inquiries Database shall
include the following items of information for each unique inquiry (Inquiry)
received for information about Elan’s Government Reimbursed Products: 1)
date of Inquiry; 2) form of Inquiry (e.g., fax, phone, etc.); 3) name of the
requesting HCP or health care institution (HCI) in accordance with
applicable privacy laws; 4) nature and topic of

-8-

 

request (including exact language of the Inquiry if made in writing); 5)
nature/form of the response from Elan (including a record of the materials
provided to the HCP or HCI in response to the request); and 6) the name of
the Elan representative who called on or interacted with the HCP or HCI, if
known;

e. the manner and circumstances under which medical personnel from Medical
Affairs interact with or participate in meetings or events with HCPs or HCIs
and the role of the medical personnel at such meetings or events, as well as
how they handle responses to requests for information about Government
Reimbursed products, including requests relating to the approved and
off-label uses of such products;

f. the funding of grants (including educational or research grants) or
charitable contributions. These Policies and Procedures shall be designed to
ensure that Elan’s funding complies with all applicable Federal health care
program and FDA requirements;

the review of product-related materials and information for or about
Government Reimbursed Products by appropriate qualified personnel (such as
regulatory, medical, and/or legal personnel) in a manner designed to ensure
that legal, regulatory, and medical concerns are properly addressed during
the review and approval process and are elevated when appropriate. These
Policies and Procedures shall be designed to ensure that such materials and
information comply with all applicable Federal health care program and FDA
requirements. The Policies and Procedures shall require that: 1) applicable
review committees review all promotional materials about Government
Reimbursed Products prior to the distribution or use of such materials in
the U.S.; and 2) deviations from the standard review committee practices and
protocols (including timetables for the submission of materials for review)
shall be documented and referred for appropriate follow-up; and

g. disciplinary policies and procedures for violations of Elan’s Policies
and Procedures, including policies relating to Federal health care program
and FDA requirements.

     Within 120 days after the Effective Date, the relevant portions of the Policies and Procedures
shall be distributed to all individuals whose job functions relate to those Policies and
Procedures. Appropriate and knowledgeable staff shall be available to explain the Policies and
Procedures.

     At least annually (and more frequently, if appropriate), Elan shall assess and update, as
necessary, the Policies and Procedures. Within 30 days after the effective date of any revisions,
the relevant portions of any such revised Policies and Procedures shall be distributed to all
individuals whose job functions relate to those Policies and Procedures.

-9-

 

     C. Training and Education.

               1. General Training. Within 90 days after the Effective Date, Elan shall provide at least two
hours of General Training to each Covered Person. This training, at a minimum, shall explain
Elan’s:

a. CIA requirements; and

b. Elan’s Compliance Program (including the Code of Conduct and the Policies
and Procedures as they pertain to general compliance issues).

     New Covered Persons shall receive the General Training described above within 30 days after
becoming a Covered Person or within 90 days after the Effective Date, whichever is later. After
receiving the initial General Training described above, each Covered Person shall receive at least
one hour of General Training in each subsequent Reporting Period.

               2. Specific Training. Within 90 days after the Effective Date, each Relevant Covered Person
engaged in Government Contracting and Pricing Functions shall receive at least two hours of
Specific Training in addition to the General Training required above. This Specific Training shall
include, at a minimum, a discussion of:

a. all applicable Federal health care program and FDA requirements relating
to Government Pricing and Contracting Functions;

b. all Elan Policies and Procedures and other requirements applicable to
Government Pricing and Contracting Functions;

c. the personal obligation of each individual involved in Government Pricing
and Contracting Functions to comply with all applicable Federal health care
program and FDA requirements and all other applicable legal requirements;

d. the legal sanctions for violations of the applicable Federal health care
program and FDA requirements; and

e. examples of proper and improper practices related to Government Pricing
and Contracting Functions.

     Within 90 days after the Effective Date, each Relevant Covered Person engaged in Medical
Affairs and Materials Related Functions shall receive at least two hours of Specific Training in
addition to the General Training required above. This Specific Training shall include, at a
minimum, a discussion of:

a. all applicable Federal health care program and FDA requirements relating
to Medical Affairs and Materials Related Functions;

b. all Elan Policies and Procedures and other requirements applicable to
Medical Affairs and Materials Related Functions;

-10-

 

c. the personal obligation of each individual involved in Medical Affairs
and Materials Related Functions to comply with all applicable Federal health
care program and FDA requirements and all other applicable legal
requirements;

d. the legal sanctions for violations of the applicable Federal health care
program and FDA requirements; and

e. examples of proper and improper practices related to Medical Affairs and
Materials Related Functions.

     New Relevant Covered Persons shall receive Specific Training as set forth above within 30 days
after the beginning of their employment or becoming Relevant Covered Persons, or within 90 days
after the Effective Date, whichever is later. An Elan employee who has completed the Specific
Training shall review a new Relevant Covered Person’s work, to the extent that the work relates to
Government Pricing and Contracting Functions or Medical Affairs and Materials Related Functions,
until such time as the new Relevant Covered Person completes his or her Specific Training.

     After receiving the initial Specific Training described in this Section, each Relevant Covered
Person shall receive at least two hours of Specific Training in each subsequent Reporting Period.

               3. Certification. Each individual who is required to attend training shall certify, in
writing, or in electronic form, if applicable, that he or she has received the required training.
The certification shall specify the type of training received and the date received. The Chief
Compliance Officer (or designee) shall retain the certifications, along with all course materials.
These shall be made available to OIG, upon request.

               4. Qualifications of Trainer. Persons providing the training shall be knowledgeable about the
subject area, including applicable Federal health care program and FDA requirements.

               5. Update of Training. Elan shall review the training annually, and, where appropriate, update
the training to reflect changes in Federal health care program requirements, FDA requirements, any
issues discovered during internal audits or any IRO Review, and any other relevant information.

               6. Computer-based Training. Elan may provide the training required under this CIA through
appropriate computer-based training approaches. If Elan chooses to provide computer-based training,
it shall make available appropriately qualified and knowledgeable staff or trainers to answer
questions or provide additional information to the individuals receiving such training.

     D. Review Procedures.

               1. General Description.

-11-

 

a. Engagement of Independent Review Organization. Within 90 days after the
Effective Date, Elan shall engage an entity (or entities), such as an
accounting, auditing, or consulting firm (hereinafter “Independent Review
Organization” or “IRO”), to perform reviews to assist Elan in assessing and
evaluating its Government Pricing and Contracting Functions, its Medical
Affairs and Materials Related Functions, and the funding of educational
grants and healthcare related charitable contributions. The applicable
requirements relating to the IRO are outlined in Appendix A to this CIA,
which is incorporated by reference.

Each IRO engaged by Elan shall have expertise in applicable Federal health
care program and FDA requirements as may be appropriate to the Review for
which the IRO is retained. Each IRO shall assess, along with Elan, whether
it can perform the engagement in a professionally independent and objective
fashion, as appropriate to the nature of the review, taking into account any
other business relationships or other engagements that may exist.

The IRO(s) shall conduct reviews that assess Elan’s systems, processes,
policies, procedures, and practices relating to Government Pricing and
Contracting Functions, Medical Affairs and Materials Related Functions, and
the funding of educational grants and healthcare related charitable
contributions (collectively “IRO Reviews”).

b. Frequency and Brief Description of Reviews. As set forth more fully in
Appendix B, the IRO Review shall consist of two components — a Systems
Review and a Transactions Review. The Systems Review shall assess Elan’s
systems, processes, policies, and procedures relating to the certain aspects
of Government Pricing and Contracting Functions and Medical Affairs and
Materials Related Functions (Systems Review). As set forth in Appendix B, if
there are no material changes in Elan’s relevant systems, processes,
policies, and procedures, the Systems Review shall be performed for the
periods covering the first and fourth Reporting Periods. If Elan materially
changes its relevant systems, processes, policies, and procedures, the IRO
shall perform a Systems Review for the Reporting Period in which such
changes were made in addition to conducting the Systems Review for the first
and fourth Reporting Periods. The Transactions Review shall be performed
annually and shall cover each of the five Reporting Periods.

In addition, each Transactions Review shall also include a review of up to
two additional areas or practices of Elan, subject to modification if Elan
undertakes additional Promotion Related Functions, related to a Government
Reimbursed Products identified by the OIG in its discretion (hereafter
“Additional Items”.) For purposes of identifying the Additional Items to be
included in the Transactions Review for a particular Reporting Period, the
OIG will consult with Elan and may consider internal audit

-12-

 

work conducted by Elan, Elan’s Government Reimbursed Products portfolio, the
nature and scope of Elan’s activities and arrangements with HCPs and HCIs
related to Government Reimbursed Products, and other information known to
it. The OIG shall notify Elan of the nature and scope of the IRO Review for
each of the Additional Items not later than 120 days prior to the end of
each Reporting Period. Prior to undertaking the review of the Additional
Items, the IRO and/or Elan shall submit an audit work plan to the OIG for
approval and the IRO shall conduct the review of the Additional Items based
on a work plan approved by the OIG.

c. Retention of Records. The IRO and Elan shall retain and make available to
OIG, upon request, all work papers, supporting documentation,
correspondence, and draft reports (those exchanged between the IRO and Elan)
related to the reviews.

          2. IRO Review Reports. The IRO(s) shall prepare a report (or reports) based upon each Review
performed. The information and content to be included in each report is described in Appendix B,
which is incorporated by reference.

          3. Validation Review. In the event OIG has reason to believe that: (a) any IRO Review fails to
conform to the requirements of this CIA; or (b) the IRO’s findings or Review results are
inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the
applicable IRO Review complied with the requirements of the CIA and/or the findings or Review
results are inaccurate (Validation Review). Elan shall pay for the reasonable cost of any such
review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted
as part of Elan’s final Annual Report shall be initiated no later than one year after Elan’s final
submission (as described in Section II) is received by OIG.

     Prior to initiating a Validation Review, OIG shall notify Elan of its intent to do so and
provide a written explanation of why OIG believes such a review is necessary. To resolve any
concerns raised by OIG, Elan may request a meeting with OIG to: (a) discuss the results of any
Review submissions or findings; (b) present any additional information to clarify the results of
the applicable Review or to correct the inaccuracy of the Review; and/or (c) propose alternatives
to the proposed Validation Review. Elan agrees to provide any additional information as may be
requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith
to resolve any Review issues with Elan prior to conducting a Validation Review. However, the final
determination as to whether or not to proceed with a Validation Review shall be made at the sole
discretion of OIG.

          4. Independence and Objectivity Certification. The IRO shall include in its report(s) to Elan
a certification or sworn affidavit that it has evaluated its professional independence and
objectivity, as appropriate to the nature of the engagement, with regard to the IRO Review and that
it has concluded that it is, in fact, independent and objective.

-13-

 

     E. Disclosure Program.

     Elan currently has a disclosure program that is designed to facilitate communications relating
to compliance with Federal health care program and FDA requirements and Elan’s policies (the
“Disclosure Program”). During the term for the CIA, Elan shall maintain a Disclosure Program that
includes a mechanism (e.g., a toll-free compliance telephone line) to enable individuals to
disclose, to the Chief Compliance Officer or some other person who is not in the disclosing
individual’s chain of command, any identified issues or questions associated with Elan’s policies,
conduct, practices, or procedures with respect to a Federal health care program or FDA requirement
believed by the individual to be a potential violation of criminal, civil, or administrative law.
Elan shall continue to appropriately publicize the existence of the disclosure mechanism
(e.g., via periodic e-mails to employees or by posting the information in prominent common
areas).

     The Disclosure Program shall emphasize a nonretaliation policy, and shall include a reporting
mechanism for anonymous communications for which appropriate confidentiality shall be maintained.
Upon receipt of a disclosure, the Chief Compliance Officer (or designee) shall gather all relevant
information from the disclosing individual. The Chief Compliance Officer (or designee) shall make
a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that
he or she has obtained all of the information necessary to determine whether a further review
should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1)
permits a determination of the appropriateness of the alleged improper practice; and (2) provides
an opportunity for taking corrective action, Elan shall conduct an internal review of the
allegations set forth in the disclosure and ensure that proper follow-up is conducted.

     The Chief Compliance Officer (or designee) shall maintain a disclosure log, which shall
include a record and summary of each disclosure received (whether anonymous or not), the status of
the respective internal reviews, and any corrective action taken in response to the internal
reviews. The disclosure log shall be made available to OIG upon request.

     F. Ineligible Persons.

          1. Definitions. For purposes of this CIA:

a. an “Ineligible Person” shall include an individual or entity who:

i. is currently excluded, debarred, suspended, or otherwise
ineligible to participate in the Federal health care programs or in
Federal procurement or nonprocurement programs; or

ii. has been convicted of a criminal offense that falls within the
scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded,
debarred, suspended, or otherwise declared ineligible.

b. “Exclusion Lists” include:

-14-

 

i. the HHS/OIG List of Excluded Individuals/Entities (available
through the Internet at http://www.oighhs.gov); and

ii. the General Services Administration’s List of Parties Excluded
from Federal Programs (available through the Internet at
http://www.epls.gov).

          2. Screening Requirements. Elan shall ensure that all prospective and current Covered Persons
are not Ineligible Persons, by implementing the following screening requirements.

a. Elan shall screen all prospective and current Covered Persons against the
Exclusion Lists prior to engaging their services and, as part of the hiring
or contracting process, shall require such Covered Persons to disclose
whether they are Ineligible Persons.

b. Elan shall screen all Covered Persons against the Exclusion Lists within
90 days after the Effective Date and on an annual basis thereafter.

c. Elan shall implement a policy requiring all Covered Persons to disclose
immediately any debarment, exclusion, suspension, or other event that makes
that person an Ineligible Person.

     Nothing in this Section affects the responsibility of (or liability for) Elan to refrain from
billing Federal health care programs for items or services furnished, ordered, or prescribed by an
Ineligible Person. Elan understands that items or services furnished by excluded persons are not
payable by Federal health care programs and that Elan may be liable for overpayments and/or
criminal, civil, and administrative sanctions for employing or contracting with an excluded person
regardless of whether Elan meets the requirements of Section III.F.

          3. Removal Requirement. If Elan has actual notice that a Covered Person has become an
Ineligible Person, Elan shall remove such Covered Person from responsibility for, or involvement
with, Elan’s business operations related to the Federal health care programs and shall remove such
Covered Person from any position for which the Covered Person’s compensation or the items or
services furnished, ordered, or prescribed by the Covered Person are paid in whole or part,
directly or indirectly, by Federal health care programs or otherwise with Federal funds at least
until such time as the Covered Person is reinstated into participation in the Federal health care
programs.

          4. Pending Charges and Proposed Exclusions. If Elan has actual notice that a Covered Person is
charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a),
1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract
term, Elan shall take all appropriate actions to ensure that the responsibilities of that Covered
Person have not and shall not adversely affect the any claims submitted to any Federal health care
program.

-15-

 

     G. Notification of Government Investigation or Legal Proceedings.

     Within 30 days after discovery, Elan shall notify OIG, in writing, of any ongoing
investigation or legal proceeding known to Elan conducted or brought by a U.S.-based governmental
entity or its agents involving an allegation that Elan has committed a crime or has engaged in
fraudulent activities. This notification shall include a description of the allegation, the
identity of the investigating or prosecuting agency, and the status of such investigation or legal
proceeding. Elan shall also provide written notice to OIG within 30 days after the resolution of
the matter, and shall provide OIG with a description of the findings and/or results of the
investigation or proceedings, if any.

     H. Reporting.

               1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means
anything that involves:

a. a matter that a reasonable person would consider a probable violation of
criminal, civil, or administrative laws applicable to any Federal health
care program for which penalties or exclusion may be authorized;

b. a matter that a reasonable person would consider a probable violation of
criminal, civil, or administrative laws applicable to any FDA requirements
relating to the promotion of Government Reimbursed Products (including an
FDA Warning Letter issued to Elan or any Elan Affiliate);

c. the employment of or contracting with a Covered Person who is an
Ineligible Person as defined by Section III.F.1.a; or

d. the filing of a bankruptcy petition by Elan.

     A Reportable Event may be the result of an isolated event or a series of occurrences.

               2. Reporting of Reportable Events. If Elan determines (after a reasonable opportunity to
conduct an appropriate review or investigation of the allegations) through any means that there is
a Reportable Event, Elan shall notify OIG, in writing, within 30 days after making the
determination that the Reportable Event exists.

               3. Reporting of Reportable Events under Sections III.1.a-c. If Elan determines (after a
reasonable opportunity to conduct an appropriate review or investigation of the allegations)
through any means that there is a Reportable Event, Elan shall notify OIG, in writing, within 30
days after making the determination that the Reportable Event exists. The report to OIG shall
include the following information:

a. complete description of the Reportable Event, including the relevant
facts, persons involved, and legal and Federal health care program
authorities and/or FDA authorities implicated;

-16-

 

b. description of Elan’s actions taken to correct the Reportable Event; and

c. any further steps Elan plans to take to address the Reportable Event and
prevent it from recurring.

     4. Reporting of Reportable Events under Section III.I.1.d. For Reportable Events under
Section III.I.l.d, the report to the OIG shall include documentation of the bankruptcy
filing and a description of any Federal health care program or FDA authorities implicated.

     I. Notification of Communications with FDA.

     Within 30 days after the date of any written report, correspondence, or communication between
Elan and the FDA that materially discusses Elan’s or a Covered Person’s actual or potential
unlawful or improper promotion of any products (including any improper dissemination of information
about off-label indications) or potential unlawful or improper distribution of Government
Reimbursed Products, Elan shall provide a copy of the report, correspondence, or communication to
the OIG. Elan shall also provide written notice to the OIG within 30 days after the resolution of
any such disclosed off-label matter, and shall provide the OIG with a description of the findings
and/or results of the matter, if any.

IV. Changes to Business Units or Locations

     A. Change or Closure of Unit or Location. In the event that, after the Effective Date,
Elan changes locations or closes a business unit or location engaged in Government Pricing or
Contracting Functions or Medical Affairs and Materials Related Functions, Elan shall notify OIG of
this fact as soon as possible, but no later than within 30 days after the date of change or closure
of the location.

     B. Purchase or Establishment of New Unit or Location. In the event that, after the
Effective Date, Elan purchases or establishes a new business unit or location engaged in Government
Pricing or Contracting Functions or Medical Affairs Related Services Related Functions, Elan shall
notify OIG no later than the earlier of the date the purchase or establishment is publicly
disclosed or the operation of the new business unit or location begins. This notification shall
include the address of the new business unit or location, phone number, fax number, Federal health
care program provider and/or supplier number, and the name and address of the contractor that
issued each number (if applicable). Each new business unit or location and all Covered Persons at
each new business unit or location shall be subject to the applicable requirements of this CIA.

     Consistent with the requirements set forth in Section I above, in the event that Elan intends
to purchase or establish a new business unit or location engaged in Promotion Related Functions in
the United States, Elan shall notify the OIG, in writing, of that intention 120 days prior to
commencing such Promotion Related Functions. Elan shall also provide information to the OIG about
the intended Promotional Related Functions. Elan agrees that it shall not engage in additional
Promotion Related Functions in the United States, until after it enters an amended CIA that
includes provisions acceptable to the OIG addressing the Promotion Related Functions.

-17-

 

     C. Sale of Unit or Location. In the event that, after the Effective Date, Elan
proposes to sell any or all of its business units or locations that are subject to this CIA, Elan
shall notify OIG of the proposed sale no later than the date the sale is publicly disclosed. This
notification shall include a description of the business unit or location to be sold, a brief
description of the terms of the sale, and the name and contact information of the prospective
purchaser. This CIA shall be binding on the purchaser of such business unit or location, unless
otherwise determined and agreed to in writing by the OIG.

V. Implementation and Annual Reports

     A. Implementation Report. Within 150 days after the Effective Date, Elan shall submit
a written report to OIG summarizing the status of its implementation of the requirements of this
CIA (Implementation Report). The Implementation Report shall, at a minimum, include:

     1. the name, address, phone number, and position description of the Chief Compliance
Officer required by Section III.A, and a summary of other noncompliance job responsibilities
the Chief Compliance Officer may have;

     2. the names and positions of the members of the Compliance Committee required by
Section III.A;

     3. the names of the members of the Audit Committee of the Board of Directors referenced
in Section III.A.3;

     4. the names and positions of the Certifying Employees required by Section III.A.4;

     5. a copy of Elan’s Code of Conduct required by Section III.B.1;

     6. the number of individuals required to complete the Code of Conduct certification
required by Section III.B.1, the percentage of individuals who have completed such
certification, and an explanation of any exceptions (the documentation supporting this
information shall be available to OIG, upon request);

     7. a) a copy of the letter (including all attachments) required by Section II.C.8 and
III.B.2 sent to each party employing Third Party Personnel; b) a list of all such existing
co-promotion and other applicable agreements; and c) a description of the entities’ response
to Elan’s letter;

     8. a summary of all Policies and Procedures required by Section (a copy of such
Policies and Procedures shall be made available to OIG upon request);

     9. the following information regarding each type of training required by Section III.C:

a. description of such training, including a summary of the topics covered,
the length of sessions, and a schedule of training sessions; and

-18-

 

b. the number of individuals required to be trained, percentage of
individuals actually trained, and an explanation of any exceptions.

A copy of all training materials and the documentation supporting this information shall be
available to OIG, upon request.

     10. the following information regarding the IRO(s): (a) identity, address, and phone
number; (b) a copy of the engagement letter; and (c) a summary and description of any and
all current and prior engagements and agreements between Elan and the IRO;

     11. a certification from the IRO regarding its professional independence and
objectivity with respect to Elan;

     12. a description of the Disclosure Program required by Section III.E;

     13. a description of the process by which Elan fulfills the requirements of Section
III.F regarding Ineligible Persons;

     14. a list of all of Elan’s locations (including locations and mailing addresses) at
which it performs Government Pricing and Contracting or Medical Affairs and Materials
Related Functions; the corresponding name under which each location is doing business; the
corresponding phone numbers and fax numbers; each location’s Federal health care provider or
supplier number(s) (if applicable), and the name and address of each Medicare contractor to
which Elan currently submits claims (if applicable);

     15. a description of Elan’s corporate structure, including identification of any parent
and sister companies, subsidiaries, and their respective lines of business; and

     16. the certifications required by Section V.C.

     B. Annual Reports. Elan shall submit to OIG annually a report with respect to the
status of, and findings regarding, Elan’s compliance activities for each of the five Reporting
Periods (Annual Report).

	 	 	Each Annual Report shall include, at a minimum:

     1. any change in the identity, position description, or other noncompliance job
responsibilities of the Chief Compliance Officer and any change in the membership of the
Compliance Committee, the Audit Committee, or the group of Certifying Employees described in
Sections III.A.2-4;

     2. a copy of the resolution by the Audit Committee required by Section III.A.3;

     3. the number of individuals required to complete the Code of Conduct certification
required by Section III.B.1, the percentage of individuals who have completed such
certification, and an explanation of any exceptions (the documentation supporting this
information shall be available to OIG, upon request);

-19-

 

     4. a summary of any significant changes or amendments to the Policies and Procedures
required by Section III.B and the reasons for such changes (e.g., change in
applicable Federal health care program or FDA requirements);

     5. a) a copy of the letter (including all attachments) required by Section II.C.8 and
III.B.2 sent to each party employing Third Party Personnel; b) a list of all such existing
co-promotion and other applicable agreements; and c) a description of the entities’ response
to Elan’s letter;

     6. the following information regarding each type of training required by Section III.C:

a. description of the initial and annual training, including a summary of
the topics covered, the length of sessions, and a schedule of training
sessions; and

b. the number of individuals required to complete the initial and annual
training, the percentage of individuals who actually completed the initial
and annual training, and an explanation of any exceptions.

A copy of all training materials and the documentation supporting this information shall be
available to OIG, upon request.

     7. a complete copy of all reports prepared pursuant to Section III.D, along with a copy
of the IRO’s engagement letter (if applicable);

     8. Elan’s response to the reports prepared pursuant to Section III.D, along with
corrective action plan(s) related to any issues raised by the reports prepared pursuant to
Section III.D;

     9. a summary and description of any and all current and prior engagements and
agreements between Elan and the IRO, if different from what was submitted as part of the
Implementation Report;

     10. a certification from the IRO regarding its professional independence and
objectivity with respect to Elan;

     11. a summary of the disclosures in the disclosure log required by Section III.E that
relate to Federal health care programs or FDA requirements;

     12. any changes to the process by which Elan fulfills the requirements of Section III.F
regarding Ineligible Persons;

     13. a summary describing any ongoing investigation or legal proceeding required to have
been reported pursuant to Section III.G. The summary shall include a description of the
allegation, the identity of the investigating or prosecuting agency, and the status of such
investigation or legal proceeding;

-20-

 

     14. a summary of Reportable Events (as defined in Section III.H) identified during the
Reporting Period and the status of any corrective and preventative action relating to all
such Reportable Events;

     15. a summary describing any communications with the FDA required to have been reported
pursuant to Section III.I. This summary shall include a description of the matter and the
status of the matter;

     16. a description of all changes to the most recently provided list of Elan’s locations
(including addresses) as required by Section V.A.13; the corresponding name under which each
location is doing business; the corresponding phone numbers and fax numbers; each location’s
Federal health care program provider number or supplier number(s) (if applicable); and the
name and address of each Federal health care program contractor to which Elan currently
submits claims (if applicable); and

     17. the certifications required by Section V.C.

     The first Annual Report shall be received by OIG no later than 60 days after the end of the
first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the
anniversary date of the due date of the first Annual Report.

     C. Certifications.

     1. Certifying Employees: In each Annual Report, Elan shall include the
certifications of Certifying Employees as required by Section III.A.4;

     2. Chief Compliance Officer: In each Implementation Report and Annual Report,
Elan shall include the following individual certification by the Chief Compliance Officer:

a. to the best of his or her knowledge, except as otherwise described in the
applicable report, Elan is in compliance with all of the requirements of
this CIA;

b. he or she has reviewed the Report and has made reasonable inquiry
regarding its content and believes that the information in the Report is
accurate and truthful;

c. Elan’s: 1) Policies and Procedures as referenced in Section III.B.2
above; 2) templates for standardized contracts and other similar documents;
and 3) the training materials used for purposes of Section III.0 all have
been reviewed by competent legal counsel and have been found to be in
compliance with all applicable Federal health care program and FDA
requirements. In addition, any materials containing claims or information
about Government Reimbursed Products intended to be disseminated outside
Elan have been reviewed by competent regulatory, medical and/or legal
personnel in accordance with applicable Policies and Procedures to ensure
that legal, medical, and regulatory concerns have been addressed

-21-

 

and elevated when required, and that the materials and information when
finally approved are in compliance with all applicable Federal health care
program and FDA requirements. If the applicable legal requirements have not
changed, after the initial review of the documents listed above, only
material changes to the documents must be reviewed by competent regulatory,
medical and/or legal personnel. The certification shall include a
description of the document(s) reviewed and approximately when the review
was completed. The documentation supporting this certification shall be
available to OIG, upon request.

     D. Designation of Information. Elan shall clearly identify any portions of its
submissions that it believes are trade secrets, or information that is commercial or financial and
privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of
Information Act (FOIA), 5 U.S.C. § 552. Elan shall refrain from identifying any information as
exempt from disclosure if that information does not meet the criteria for exemption from disclosure
under FOIA.

VI. Notifications and Submission of Reports

     Unless otherwise stated in writing after the Effective Date, all notifications and reports
required under this CIA shall be submitted to the following entities:

	 	 	 	 	 

	 

	 	OIG:
	 	Administrative and Civil Remedies Branch 

Office of Counsel to the Inspector General 

Office of Inspector  General 

U.S. Department of Health and Human Services 

Cohen Building, Room 5527
	 

	 	 	 	330 Independence Avenue, S.W.
	 

	 	 	 	Washington, DC 20201
	 

	 	 	 	Telephone: 202.619.2078
	 

	 	 	 	Facsimile: 202.205.0604
	 
	 	 	 	 
	 

	 	Elan:
	 	Fabiana Lacerca-Allen
	 

	 	 	 	Senior Vice President and Chief Compliance Officer
	 

	 	 	 	800 Gateway Boulevard
	 

	 	 	 	South San Francisco, CA 94080
	 

	 	 	 	Telephone: 650.616.5006

Unless otherwise specified, all notifications and reports required by this CIA may be made by
certified mail, overnight mail, hand delivery, or other means, provided that there is proof that
such notification was received. For purposes of this requirement, internal facsimile confirmation
sheets do not constitute proof of receipt. Upon request by OIG, Elan may be required to provide OIG
with an electronic copy of each notification or report required by this CIA in searchable portable
document format (pdf), either instead of or in addition to, a paper copy.

-22-

 

VII. OIG Inspection, Audit, and Review Rigths

     In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its
duly authorized representative(s) may examine or request copies of Elan’s books, records, and other
documents and supporting materials and/or conduct on-site reviews of any of Elan’s locations for
the purpose of verifying and evaluating: (a) Elan’s compliance with the terms of this CIA; and (b)
Elan’s compliance with the requirements of the Federal health care programs in which it
participates and with all applicable FDA requirements. The documentation described above shall be
made available by Elan to OIG or its duly authorized representative(s) at all reasonable times for
inspection, audit, or reproduction. Furthermore, for purposes of this provision, OIG or its duly
authorized representative(s) may interview any of Elan’s employees, contractors, or agents who
consent to be interviewed at the individual’s place of business during normal business hours or at
such other place and time as may be mutually agreed upon between the individual and OIG. Elan shall
assist OIG or its duly authorized representative(s) in contacting and arranging interviews with
such individuals upon OIG’s request. Elan’s employees may elect to be interviewed with or without a
representative of Elan present.

VIII. Document and Record Retention

     Elan shall maintain for inspection all documents and records relating to reimbursement from
the Federal health care programs, or to compliance with this CIA, for six years (or longer if
otherwise required by law) from the Effective Date.

IX. Disclosures

     Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a
reasonable effort to notify Elan prior to any release by OIG of information submitted by Elan
pursuant to its obligations under this CIA and identified upon submission by Elan as trade secrets,
or information that is commercial or financial and privileged or confidential, under the FOIA
rules. With respect to such releases, Elan shall have the rights set forth at 45 C.F.R. § 5.65(d).

X. Breach and Default Provisions

     Elan is expected to fully and timely comply with all of its CIA obligations. The breach and
default remedies available to the OIG under this Section X do not preempt any action that
individual States may take against Elan under any applicable settlement agreement between the State
and Elan.

     A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a
contractual remedy, Elan and OIG hereby agree that failure to comply with certain obligations as
set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter
referred to as “Stipulated Penalties”) in accordance with the following provisions.

     1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the
date the obligation became due) for each day Elan fails to establish and implement any of
the following obligations as described in Section III:

-23-

 

a. a Chief Compliance Officer;

b. a Compliance Committee;

c. the Audit Committee resolution;

d. a written Code of Conduct;

e. written Policies and Procedures;

f. the training of Covered Persons and Relevant Covered Persons;

g. a Disclosure Program;

h. Ineligible Persons screening and removal requirements;

i. notification of Government investigations or legal proceedings;

j. reporting of Reportable Events; and

k. notification of communications with the FDA as specified in Section
III.I.

     2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the
date the obligation became due) for each day Elan fails to engage an IRO, as required in
Section III.D, Appendix A, and Appendix B.

     3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the
date the obligation became due) for each day Elan fails to submit the Implementation Report
or any Annual Reports to OIG in accordance with the requirements of Section V by the
deadlines for submission.

     4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the
date the obligation became due) for each day Elan fails to submit the annual IRO Review
Report(s) in accordance with the requirements of Section III.D and Appendix B.

     5. A Stipulated Penalty of $1,500 for each day Elan fails to grant access as required
in Section VII. (This Stipulated Penalty shall begin to accrue on the date Elan fails to
grant access.)

     6. A Stipulated Penalty of $5,000 for each false certification submitted by or on
behalf of Elan as part of its Implementation Report, Annual Report, additional documentation
to a report (as requested by the OIG), or otherwise required by this CIA.

     7. A Stipulated Penalty of $1,000 for each day Elan fails to comply fully and
adequately with any obligation of this CIA. OIG shall provide notice to Elan stating the
specific grounds for its determination that Elan has failed to comply fully and adequately
with the CIA obligation(s) at issue and steps Elan shall take to comply with the CIA.

-24-

 

(This Stipulated Penalty shall begin to accrue 10 days after Elan receives this notice
from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection
shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under
Subsections 1-6 of this Section.

     B. Timely Written Requests for Extensions. Elan may, in advance of the due date,
submit a timely written request for an extension of time to perform any act or file any
notification or report required by this CIA. Notwithstanding any other provision in this Section,
if OIG grants the timely written request with respect to an act, notification, or report,
Stipulated Penalties for failure to perform the act or file the notification or report shall not
begin to accrue until one day after Elan fails to meet the revised deadline set by OIG.
Notwithstanding any other provision in this Section, if OIG denies such a timely written request,
Stipulated Penalties for failure to perform the act or file the notification or report shall not
begin to accrue until three business days after Elan receives OIG’s written denial of such request
or the original due date, whichever is later. A “timely written request” is defined as a request in
writing received by OIG at least five business days prior to the date by which any act is due to be
performed or any notification or report is due to be filed.

     C. Payment of Stipulated Penalties.

     1. Demand Letter. Upon a finding that Elan has failed to comply with any of the
obligations described in Section X.A and after determining that Stipulated Penalties are
appropriate, OIG shall notify Elan of: (a) Elan’s failure to comply; and (b) OIG’s exercise
of its contractual right to demand payment of the Stipulated Penalties (this notification is
referred to as the “Demand Letter”).

     2. Response to Demand Letter. Within 10 days after the receipt of the Demand Letter,
Elan shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable
Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ)
to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set
forth below in Section X.E. In the event Elan elects to request an ALJ hearing, the
Stipulated Penalties shall continue to accrue until Elan cures, to OIG’s satisfaction, the
alleged breach in dispute. Failure to respond to the Demand Letter in one of these two
manners within the allowed time period shall be considered a material breach of this CIA and
shall be grounds for exclusion under Section X.D.

     3. Form of Payment. Payment of the Stipulated Penalties shall be made by electronic
funds transfer to an account specified by OIG in the Demand Letter.

     4. Independence from Material Breach Determination. Except as set forth in Section
X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise
set a standard for OIG’s decision that Elan has materially breached this CIA, which decision
shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D,
below.

-25-

 

     D. Exclusion for Material Breach of this CIA.

     1. Definition of Material Breach. A material breach of this CIA means:

a. a failure by Elan to report a Reportable Event and take corrective action
as required in Section III.H;

b. a repeated or flagrant violation of the obligations under this CIA,
including, but not limited to, the obligations addressed in Section X.A;

c. a failure to respond to a Demand Letter concerning the payment of
Stipulated Penalties in accordance with Section X.C;

d. a failure to engage and use an IRO in accordance with Section III.D; or

e. a failure of the Audit Committee to issue a resolution in accordance with
Section III.A.3.

     2. Notice of Material Breach and Intent to Exclude. The parties agree that a material
breach of this CIA by Elan constitutes an independent basis for Elan’s exclusion from
participation in the Federal health care programs. Upon a determination by OIG that Elan has
materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify
Elan of: (a) Elan’s material breach; and (b) OIG’s intent to exercise its contractual right
to impose exclusion (this notification is hereinafter referred to as the “Notice of Material
Breach and Intent to Exclude”).

     3. Opportunity to Cure. Elan shall have 30 days from the date of receipt of the Notice
of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction that:

a. Elan is in compliance with the obligations of the CIA cited by OIG as
being the basis for the material breach;

b. the alleged material breach has been cured; or

c. the alleged material breach cannot be cured within the 30-day period, but
that: (i) Elan has begun to take action to cure the material breach; (ii)
Elan is pursuing such action with due diligence; and (iii) Elan has provided
to OIG a reasonable timetable for curing the material breach.

     4. Exclusion Letter. If, at the conclusion of the 30-day period, Elan fails to satisfy
the requirements of Section X.D.3, OIG may exclude Elan from participation in the Federal
health care programs. OIG shall notify Elan in writing of its determination to exclude Elan
(this letter shall be referred to hereinafter as the “Exclusion Letter”). Subject to the
Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30
days after the date of Elan’s receipt of the Exclusion Letter. The exclusion shall have
national effect and shall also apply to all other Federal procurement and nonprocurement
programs. Reinstatement to program participation is not automatic.

-26-

 

After the end of the period of exclusion, Elan may apply for reinstatement by
submitting a written request for reinstatement in accordance with the provisions at 42
C.F.R. §§ 1001.3001-.3004.

     E. Dispute Resolution

     1. Review Rights. Upon OIG’s delivery to Elan of its Demand Letter or of its Exclusion
Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising
under this CIA, Elan shall be afforded certain review rights comparable to the ones that are
provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the
Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s
determination to demand payment of Stipulated Penalties or to seek exclusion shall be
subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals
Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21.
Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving
Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the
request for a hearing involving exclusion shall be made within 25 days after receipt of the
Exclusion Letter.

     2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United
States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding
for Stipulated Penalties under this CIA shall be: (a) whether Elan was in full and timely
compliance with the obligations of this CIA for which OIG demands payment; and (b) the
period of noncompliance. Elan shall have the burden of proving its full and timely
compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the
right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties. If the
ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Elan to pay
Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after
the ALJ issues such a decision unless Elan requests review of the ALJ decision by the DAB.
If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of
OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its
decision.

     3. Exclusion Review. Notwithstanding any provision of Title 42 of the United States
Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for
exclusion based on a material breach of this CIA shall be:

a. whether Elan was in material breach of this CIA;

b. whether such breach was continuing on the date of the Exclusion Letter;
and

c. whether the alleged material breach could not have been cured within the
30-day period, but that: (i) Elan had begun to take action to cure the
material breach within that period; (ii) Elan has pursued and is pursuing
such action with due diligence; and (iii) Elan provided to OIG within that

-27-

 

period a reasonable timetable for curing the material breach and Elan has
followed the timetable.

     For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision
favorable to OIG, or, if the ALJ rules for Elan, only after a DAB decision in favor of OIG. Elan’s
election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to
exclude Elan upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the
determination of OIG and determines that exclusion is authorized, such exclusion shall take effect
20 days after the ALJ issues such a decision, notwithstanding that Elan may request review of the
ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the
exclusion shall take effect 20 days after the DAB decision. Elan shall waive its right to any
notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If
the DAB finds in favor of Elan, Elan shall be reinstated effective on the date of the original
exclusion.

     4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be
considered to be an appeal right arising under any statutes or regulations. Consequently,
the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not
appealed) shall be considered final for all purposes under this CIA.

XI. Effective and Binding Agreement 

     Elan and OIG agree as follows:

     A. This CIA shall be binding on the successors, assigns, and transferees of Elan;

     B. This CIA shall become final and binding on the date the final signature is obtained on the
CIA;

     C. This CIA constitutes the complete agreement between the parties and may not be amended
except by written consent of the parties to this CIA;

     D. The undersigned Elan signatories represent and warrant that they are authorized to execute
this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official
capacity and that he is authorized to execute this CIA.

     E. This CIA may be executed in counterparts, each of which constitutes an original and all of
which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable,
binding signatures for purposes of this CIA.

-28-

 

On Behalf of Elan Corporation

	 	 	 	 	 

	     /s/ John B. Moriarty, Jr.
 

JOHN B. MORIARTY, JR.

	 	December 14, 2010
 

DATE
	 	 
	Senior Vice President and General Counsel
	 	 	 	 
	Elan Corporation, plc
	 	 	 	 
	 
	 	 	 	 
	     /s/ Fabiana Lacerca-Allen
 

FABIANA LACERCA-ALLEN

	 	December 14, 2010
 

DATE
	 	 
	Chief Compliance Officer
	 	 	 	 
	Elan Corporation, plc
	 	 	 	 
	 
	 	 	 	 
	     /s/ John S. Rah
 

JOHN S. RAH

	 	December 14, 2010
 

DATE
	 	 
	Morgan Lewis & Bockius
	 	 	 	 
	Counsel for Elan Corporation, plc
	 	 	 	 
	 
	 	 	 	 
	     /s/ Joshua S. Levy
 

JOSHUA S. LEVY

	 	December 14, 2010
 

DATE
	 	 
	Ropes & Gray, LLP
	 	 	 	 
	Counsel for Elan Corporation, plc
	 	 	 	 

-29-

 

On behalf of the Office of Inspector General

of the Department of Health and Human Services

	 	 	 	 	 

	     /s/ Gregory E. Demske
 

GREGORY E. DEMSKE

	 	December 15, 2010
 

DATE
	 	 
	Assistant Inspector General for Legal Affairs 

Office of Inspector General
	 	 	 	 
	U. S. Department of Health and Human Services
	 	 	 	 

-30-

 

APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO)
required by Section III.D of the CIA.

A. IRO Engagement.

     Elan shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to
perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a
professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after
OIG receives the information identified in Sections V.A.10 and V.A.11 of the CIA, OIG will notify
Elan if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Elan
may continue to engage the IRO.

     If Elan engages a new IRO during the term of the CIA, this IRO shall also meet the
requirements of this Appendix. If a new IRO is engaged, Elan shall submit the information
identified in Sections V.A.10 and V.A.11 of the CIA to OIG within 30 days of engagement of the IRO.
Within 30 days after OIG receives this information, OIG will notify Elan if the IRO is
unacceptable. Absent notification from OIG that the IRO is unacceptable, Elan may continue to
engage the IRO.

B. IRO Qualifications.

The IRO shall:

     1. assign individuals to conduct the IRO Reviews who have expertise in all applicable Federal
health care program and FDA requirements relating to Government Pricing and Contracting Related
Functions, Medical Affairs and Materials Related Functions, and the funding of educational grants
and healthcare related charitable contributions. The assigned individuals shall also be
knowledgeable about the general requirements of the Federal health care program(s) under which Elan
products are reimbursed;

     2. assign individuals to design and select the samples for the Transaction Reviews who are
knowledgeable about the appropriate statistical sampling techniques; and

     3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely
basis.

C. IRO Responsibilities.

The IRO shall:

     1. perform each component of the IRO Review in accordance with the specific requirements of
the CIA;

1

 

     2. follow all applicable Federal health care program and FDA requirements in making
assessments in each IRO Review;

     3. if in doubt of the application of a particular Federal health care program or FDA
requirement, policy, or regulation, request clarification from the appropriate authority
(e.g., CMS or FDA);

     4. respond to all OIG inquires in a prompt, objective, and factual manner; and

     5. prepare timely, clear, well-written reports that include all the information required by
Appendix B to the CIA.

D. IRO Independence and Objectivity.

The IRO must perform the IRO Reviews in a professionally independent and objective fashion, as
appropriate to the nature of the engagement, taking into account any other business relationships
or engagements that may exist between the IRO and Elan.

E. IRO Removal/Termination.

     1. Elan Termination of IRO. If Elan terminates its IRO during the course of the engagement,
Elan must submit a notice explaining its reasons to OIG no later than 30 days after termination.
Elan must engage a new IRO in accordance with Paragraph A of this Appendix.

     2. OIG Removal of IRO. In the event OIG has reason to believe that the IRO does not possess
the qualifications described in Paragraph B, is not independent and/or objective as set forth in
Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may,
at its sole discretion, require Elan to engage a new IRO in accordance with Paragraph A of this
Appendix.

     Prior to requiring Elan to engage a new IRO, OIG shall notify Elan of its intent to do so and
provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns
raised by OIG, Elan may request a meeting with OIG to discuss any aspect of the IRO’s
qualifications, independence or performance of its responsibilities and to present additional
information regarding these matters. Elan shall provide any additional information as may be
requested by OIG under this Paragraph in an expedited manner. OIG will attempt in good faith to
resolve any differences regarding the IRO with Elan prior to requiring Elan to terminate the IRO.
However, the final determination as to whether or not to require Elan to engage a new IRO shall be
made at the sole discretion of OIG.

-2-

 

Appendix B to CIA

I. General Description

As specified more fully below, Elan shall retain an Independent Review Organization (IRO) to
perform reviews to assist Elan in assessing and evaluating its systems, processes, policies,
procedures, and practices related to Government Pricing and Contracting Functions (as defined in
Section II.C.4 of the CIA), its Medical Affairs and Materials Related Functions (as defined in
Section II.C.5 of the CIA), and its funding of educational grants and healthcare related charitable
contributions (as discussed below in Section III.A) (collectively “IRO Reviews”). The IRO Review
shall consist of two components — a systems review (Systems Review) and a transactions review
(Transactions Review) as described more fully below. Elan may engage, at its discretion, a single
IRO to perform both components of the IRO Review provided that the entity has the necessary
expertise and capabilities to perform both.

If, during the term of the CIA, there are no material changes in Elan’s systems, processes,
policies, and procedures relating to Government Pricing and Contracting Functions or to Medical
Affairs and Materials Related Functions, the IRO shall perform the Systems Review for the first and
fourth Reporting Periods. If Elan materially changes its systems, processes, policies, and
procedures relating to Government Pricing and Contracting Functions or to Medical Affairs or
Materials Related Functions, the IRO shall perform a Systems Review for the materially changed
Function for the Reporting Period(s) in which such changes were made in addition to conducting the
Review for the first and fourth Reporting Periods. The additional Systems Review(s) shall consist
of: 1) an identification of the material changes; 2) an assessment of whether other systems,
processes, policies, and procedures previously reported did not materially change; and 3) a review
of the systems, processes, policies, and procedures that materially changed. The IRO shall conduct
the Transactions Review for each Reporting Period of the CIA.

II. Systems Review

The Systems Review shall be a review of Elan’s systems, processes, policies, and procedures
(including the controls on those systems, processes, policies, and procedures) relating to certain
Government Pricing and Contracting Functions and to certain Medical Affairs and Materials Related
Functions. Where practical, Elan personnel may compile documentation, schedule and organize
interviews, and undertake other efforts to assist the IRO in performing the Systems Review. The IRO
is not required to undertake a de novo review of the information gathered or activities
undertaken by Elan pursuant to the preceding sentence.

A. Systems Review — Part 1 (relating to Government Pricing and Contracting Functions)

The IRO shall review Elan’s systems, processes, policies, and procedures (including the
controls on the systems, processes, policies, and procedures) associated with the tracking,
gathering, and accounting for all relevant data for purposes of calculating and reporting
Average Manufacturer Price (AMP), Best Price, and Average Sales Price (ASP) to CMS (known as
“Reviewed Policies and Procedures”). More specifically, the IRO shall review

-1-

 

the following for Elan’s Government Reimbursed Products as defined in Section II.C.3 of the
CIA.

     1. The systems, processes, policies, and procedures used to determine which Elan
customers are included or excluded for purposes of determining AMP, BP, and ASP;

     2. The systems, policies, processes, and procedures used to determine whether and which
particular transactions (discounts, rebates) are included in or excluded from AMP, BP, and
ASP determinations;

     3. A review of Elan’s methodology for applying transactions to the AMP, BP, and ASP
determinations;

     4. A review of Elan’s methodology for estimating any prices, discounts, or other
amounts used in determining AMP, BP, and ASP;

     5. The flow of data and information by which price, contract terms, and transactions
with Elan customers are accumulated from the source systems and entered and tracked in
Elan’s information systems for purposes of determining AMP, BP, and ASP;

     6. A review of any Elan inquiries to CMS regarding AMP, BP, and ASP determinations and
reporting requirements, including requests for interpretation or guidance, and any responses
to those inquiries; and

     7. The controls and processes in place to examine and address system reports that
require critical evaluation (such as reports of variations, exceptions, or outliers). This
shall include a review of the bases upon which variations, exceptions, and outliers are
identified and the follow-up actions undertaken to identify the cause of any variations.

B. Systems Review — Part 2 (relating to Medical Affairs Related Functions)

The IRO shall review Elan’s systems, processes, policies, and procedures (including the
controls on those systems, processes, policies, and procedures) relating to the following
Medical Affairs and Materials Related Functions (known as “Reviewed Policies and
Procedures”):

     1. Elan’s systems, policies, processes, and procedures applicable to the manner in
which Elan representatives (including Medical Affairs personnel, Clinical Science Liaisons
(CSLs), and/or headquarters personnel) handle requests for information or inquiries about
the uses of Government Reimbursed Products in the United States (including the off-label
uses of the products) and any dissemination of materials relating to the uses of such
products in the United States.

     This review includes:

a. the manner in which CSLs and headquarters personnel (including Medical
Affairs personnel) with responsibility for the U.S. market receive

-2-

 

and respond to requests for information about the uses of Government
Reimbursed Products, including any off-label uses of such products;

b. the form and content of product-related infoiniation disseminated by Elan
or its agents to U.S.-based HCPs or U.S.-based HCIs;

c. Elan’s internal review and approval process relating to materials and
information about Elan’s products that Elan personnel disseminate to HCPs or
HCIs in the U.S, including reviews that occur through review committee
process;

d. Elan’s systems, processes, and procedures (including the Inquiries
Database) to track requests from U.S.-based HCPs, HCI’s or other persons for
information about the uses of products in the U.S. and responses to those
requests;

e. the manner in which Elan collects and supports information reported in
any systems used to track and respond to requests for product information,
including its Inquiries Database;

f. systems, processes, policies, and procedures applicable to the functions
of Elan’s CSLs; the manner and circumstances under which CSLs or personnel
from Elan’s Medical Affairs group interact with or participate in meetings
or events with HCPs or HCIs; and the role of such personnel at such meetings
or events. This review shall include a review of any internal monitoring
plan designed to monitor the activities of Medical Affairs personnel;

g. the processes and procedures by which the Chief Compliance Officer (and
other appropriate individuals within Elan) identify and monitor situations
in which it appears that improper promotion may have occurred in the United
States; and

h. Elan’s processes and procedures for investigating, documenting,
resolving, and taking appropriate disciplinary action for potential
situations involving improper promotion in the United States.

C. Systems Review Report.

The IRO shall prepare a report based upon both Parts 1 and 2 of each Systems Review.

For each of the topics identified in Section II.A above, the report shall include the
following items:

     1. A description of the methodology, systems, processes, policies, and practices in
place to calculate, track, gather, and account for price terms, contract terms, and
transactions with Elan customers that are relevant to the calculation and reporting of AMP,
Best Price, and ASP, including, but not limited to:

-3-

 

a. The computer or other relevant systems (including the source systems and
any other information systems, as applicable) used to track data for and to
calculate and report AMP, Best Price, and ASP;

b. The information input into Elan’s relevant computer or other systems used
to calculate AMP, Best Price and ASP;

c. The system logic or decisional rationale used to determine which
customers are included or excluded for purposes of calculating AMP, Best
Price, and ASP;

d. The system logic or decisional rationale used to determine whether
contract terms, discounts, rebates and all other relevant transactions with
Elan customers are included or excluded when calculating AMP, Best Price,
and ASP; and

e. Elan’s policies and practices in examining system reports for variations
that require critical evaluation, including the basis on which variations,
exceptions, or outliers are identified, and the follow up actions taken in
response.

     2. A description of the documentation, information, and systems reviewed, and the
personnel interviewed, if any, including a description of the following:

a. Elan’s inquires to CMS or any State Medicaid program regarding the
calculation of AMP, Best Price, and/or ASP and any responses to those
inquiries;

b. Elan’s systems and practices for reporting AMP, Best Price, and ASP to
CMS as required by the Medicaid Drug Rebate program and the Medicare Part B
program; and

c. Elan’s systems and practices for reporting any adjustments or additional
information related to the AMP, Best Price, and ASP submissions.

     3. Observations, findings, and recommendations for any improvements to Elan’s systems,
processes, policies, and practices, including any changes recommended in order to improve
compliance with the requirements of the Medicaid Program, the Medicaid Drug Rebate program,
or the Medicare Part B program.

For each of the Reviewed Policies and Procedures identified in Section II.B above, the
report shall include the following items:

     1. a description of the documentation (including policies) reviewed and any personnel
interviewed;

-4-

 

     2. a detailed description of Elan’s systems, policies, processes, and procedures
relating to the items identified in Section II. B above, including a general description of
Elan’s control and accountability systems (e.g., documentation and approval
requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies
and Procedures;

     3. a description of the manner in which the control and accountability systems and the
written policies relating to the items identified in Section II.B.1 above are made known or
disseminated within Elan;

     4. a detailed description of any system(s) used to track and respond to requests and
inquiries regarding off-label uses of Elan products;

     5. findings and supporting rationale regarding any weaknesses in Elan’s systems,
processes, policies, and procedures relating to the Reviewed Policies and Procedures, if
any; and

     6. recommendations to improve any of the systems, policies, processes, or procedures
relating to the Reviewed Policies and Procedures, if any.

III. IRO Transactions Review

As described more fully below in Sections III.A-B, the Transactions Review shall include: (1) a
review of Control Documents for a sample of external funding requests that were paid by Elan during
the applicable Review Period for educational grants and healthcare related charitable
contributions; and (2) a review of up to two additional items identified by the OIG in accordance
with Section III.D.1.b of the CIA (hereafter “Additional Items”.) The IRO shall report on all
aspects of its reviews in the Transactions Review Reports.

     A. Review of External Funding Activities

	 	1.	 	Review of External Funding Activities
	 
	 	 	 	Elan has developed policies and procedures relating to its
funding (direct and indirect) of educational grants and
healthcare related charitable contributions. A healthcare-related
charitable contribution is defined as a contribution provided to
a healthcare organization or for a function that is related to
healthcare.
	 
	 	 	 	For each Reporting Period, the IRO shall select and review a
random sample of twenty percent of the total number of paid
educational grants and charitable contributions or 25 grants and
charitable contributions, whichever is a larger number, that were
paid by Elan during the Reporting Period. For purposes of this
review, the number of grants and charitable contributions to be
reviewed by the IRO shall be in the same proportion as the

-5-

 

	 	 	 	overall number of grants and charitable contributions paid by
Elan for the applicable Reporting Period.
	 
	 	2.	 	Control Documents
	 
	 	 	 	For purposes of the IRO Review, the term “Control Documents”
shall include all documents or electronic records (collectively
“documents”) associated with each funded educational grant and
charitable contribution that are necessary to: 1) review and
evaluate: the request for funding; 2) make an approval decision
for the funding request; 3) ensure that the funding was used for
the stated purpose (e.g., an event to be funded by a charitable
contribution actually occurred); and 4) ensure that work product
generated in connection with the grant or charitable contribution
was collected and used for intended purpose. For example, Control
Documents could include, but would not be limited to, funding
request letters, grant applications, business rationale forms,
written contracts relating to the grant or charitable
contribution, budget information, documentation that the event
funded by the grant or contribution occurred, and documents
reflecting any work product generated as a result of the funding.
Each set of Control Documents relating to a particular
educational grant or charitable contribution shall be referred to
as a Sample Unit.
	 
	 	3.	 	Review of Reviewed Activities Control Documents
	 
	 	 	 	For each Sample Unit, the IRO shall review the Control Documents
to determine:

a. whether all required Control Documents associated with the educational
grant or charitable contribution exist in appropriate files in accordance
with Elan’s policies;

b. whether all required Control Documents associated with the educational
grant or charitable contribution were completed and archived in accordance
with the requirements set forth in Elan’s policies; and

c. whether the Control Documents associated with the educational grant or
charitable contribution reflect that all required written approvals were
obtained in accordance with Elan’s policies.

	 	4.	 	Identification of Material Errors and Additional Engagement
	 
	 	 	 	Any Sample Unit that does not satisfy the criteria set forth
above in Section III.A.3 shall be considered an exception and
shall be so denoted by the IRO. The IRO will consider a Control

-6-

 

	 	 	 	Document to have a Material Error if either of the following is
identified:

a. all the appropriate and required Control Documents relating to a
educational grant or charitable contribution do not exist and (i) no
corrective action has been taken prior to the IRO review; or (ii) the IRO
cannot confirm that Elan has otherwise followed its policies and procedures;
or

b. information or data is omitted from key fields in the Control Documents
that prevents the IRO from understanding the nature of the expenditure
and/or assessing compliance with Elan’s Policies and Procedures.

	 	 	 	If the IRO finds any Material Errors, it shall conduct an
Additional Engagement to review the expenditures or activities
reflected in the erroneous Sample Unit. The IRO shall perform
this Additional Engagement in a manner designed to determine the
root cause of the Material Errors. For instance, the IRO may need
to review additional documentation and/or conduct interviews with
appropriate personnel (e.g., CSLs, other Medical Affairs
personnel, or supervisors) to identify the root cause(s) of the
errors.

B. IRO Review of Additional Items

As set forth in Section III.D.1.b of the CIA, for each Reporting Period, the OIG at its
discretion may identify up to two additional items for the IRO to review (hereafter
“Additional Items”.) No later than 120 days prior to the end of the applicable Reporting
Period, the OIG shall notify Elan of the nature and scope of the IRO review to be conducted
for each of the Additional Items. Prior to undertaking the review of the Additional Items,
the IRO and/or Elan shall submit an audit work plan to the OIG for approval and the IRO
shall conduct the review of the Additional Items based on a work plan approved by the CMG.
The IRO shall include information about its review of each Additional Item in the
Transactions Review Report as specified below in Section III.C.

Elan may propose to the OIG that its internal audit(s) and/or reviews be substituted,
subject to the Verification Review requirements set forth below, for one or more of the
Additional Items that would otherwise be reviewed by the IRO for the applicable Reporting
Period. The OIG retains sole discretion over whether, and in what manner, to allow Elan’s
internal audit work and monitoring activities to be substituted for a portion of the
Additional Items review conducted by the IRO.

In making its decision, the OIG agrees to consider, among other factors, the nature and
scope of Elan’s planned monitoring activities and internal audit work, the results of the
Transactions Review(s) during prior Reporting Period(s), and Elan’s demonstrated audit
capabilities to perform the proposed audit work internally. If the OIG denies Elan’s

-7-

 

request to permit its monitoring activities or internal audit work to be substituted for a
portion of the IRO’s review of Additional Items in a given Reporting Period, Elan shall
engage the IRO to perform the Review as outlined in this Section III.B

If the OIG agrees to permit certain of Elan’s monitoring activities or internal audit work
for a given Reporting Period to be substituted for a portion of Additional Items review,
such internal work would be subject to verification by the IRO (Verification Review). In
such an instance, the OIG would provide additional details about the scope of the
Verification Review to be conducted by the IRO. However, for purposes of any Verification
Review, the IRO shall review at least 20% of the sampling units reviewed by Elan in its
internal audits.

C. IRO Transactions Review Report

For each Reporting Period, the IRO shall prepare a report based on its Transactions Review.
The report shall include the following:

	 	1.	 	General Elements to Be Included in Report

a. Review Objectives: A clear statement of the objectives intended to be
achieved by each part of the review;

b. Review Protocol: A detailed narrative description of the procedures
performed and a description of the sampling units and universes utilized in
performing the procedures for each sample reviewed; and

c. Sources of Data: A full description of documentation and other
information, if applicable, relied upon by the IRO in performing the
Transactions Review.

	 	2.	 	Results to be Included in Report
	 
	 	 	 	The following results shall be included in each Transactions
Review Report:
	 
	 	 	 	(Relating to the Review of External Funding Requests)

a. a description of each Sample Unit reviewed, the number of Sample Units
reviewed for educational grants and for charitable contributions, and an
identification of the types of Control Documents reviewed for each Sample
Unit;

b. for each Sample Unit, the IRO shall state its findings and supporting
rationale as to whether: (i) all required Control Documents exist; (ii) each
Control Document was completed in accordance with all requirements set forth
in the applicable Elan’s policy; (iii) each Control Document reflects that
Elan’s policies were followed in connection with the underlying grant or
charitable contribution (e.g., all required approvals were obtained and

-8-

 

any events funded by the monies occurred); and (iv) any disciplinary action
was taken in those instances in which an Elan policy was not followed;

c. for each Sample Unit reviewed, the IRO shall identify and describe all
exceptions discovered. The IRO shall describe those situations where
corrective action was taken prior to the IRO review, including a description
of the circumstances requiring corrective action and the nature of the
corrective action. The IRO shall also describe the situations in which it
attempted to confirm whether Elan otherwise followed its policies and
procedures, and the steps undertaken by the IRO to make that determination;

d. if any Material Errors were discovered for any Sample Unit, the IRO shall
describe the Material Error in detail and shall describe the Additional
Engagement that it performed, including any interviews conducted. The IRO
shall state its findings as to the root cause of each Material Error(s);

e. the findings and supporting rationale regarding any weaknesses in Elan’s
systems, processes, policies, and practices relating to the funding of
educational grants or charitable contributions, if any; and

f. recommendations for improvement in Elan’s systems, processes, policies,
and practices relating to the funding of educational grants or charitable
contributions, if any.

(Relating to the Additional Items Review)

g. for each Additional Item reviewed, a description of the review conducted;

h. for each Additional Item reviewed, the IRO’s findings based on its
review;

i. for each Additional Item reviewed, the findings and supporting rationale
regarding any weaknesses in Elan’s systems, processes; and

j. for each Additional Item reviewed, recommendations, if any, for changes
in Elan’s systems, processes, policies, and procedures that would correct or
address any weaknesses or deficiencies uncovered during the review.

-9-exv4wcw27

Exhibit 4(c)(27)

Memorandum of Understanding

Dated: 17 September, 2010

	 	 	 

	Parties :

	 	Elan Corporation plc (Elan)
	 

	 	Jack Schuler
	 

	 	Vaughn Bryson

Undertakings:

	1.	 	The Irish High Court litigation (2010 No. 8327P) the “Litigation”) will be stayed
until further order of the Court. All orders of the High Court in connection with the
Litigation will be suspended with liberty to Elan to reapply for their reinstatement in the
event that the proceedings are recommenced in accordance with Clause 6 below. The Litigation
is to be dismissed as set forth below. The Parties shall not assert any claims against each
other anywhere other than in the Irish High Court, save for claims pursuant to the
Confidentiality Agreement dated 8th June 2009 between which remains subject to New
York Law and jurisdiction.

	2.	 	The Parties agree to the issuance of the press release attached hereto (the “Press Release”),
and shall make no other public statements regarding the resolution of their differences except
as may be required by law.

	3.	 	Schuler and Bryson have indicated their desire to resign as directors of Elan, but shall
remain on the Board at the pleasure of the Chairman, but for no longer than 90 days from the
date hereof, and commit to resign at the Chairman’s request prior to such 90th day
or upon election of a new Chairman, whichever occurs first, and agree to sign undated
Director’s resignation letters (to be dated by the Chairman) in that respect.

	 	4.	 	Schuler, Bryson and Elan agree to continue to honour and be bound by the June 8, 2009
Letter Agreement and Confidentiality Agreement, except that all references to December
31, 2009 shall be changed to January 1, 2012. The Parties acknowledge that Schuler is a
business partner and friend of several significant investors in Elan and that he has
regular contacts and communications with such

 

 

	 	 	 	investors, and that such contacts and communications with investors shall not in and of
themselves violate the terms of the Letter Agreement except to the extent that they in
fact breach Schuler’s obligations under the Letter Agreement.

	5.	 	Should Elan believe that, after the date hereof, Schuler and/or Bryson has materially
breached any obligation, then Elan shall refer the matter to a Committee of three independent
directors of Elan (comprised of Patrick Kennedy, Dennis Selkoe and Richard Pilnik). Should
any member of the Committee cease to be a director, Elan’s Board of Directors shall select an
independent director to replace him. The Committee shall determine within 72 hours of
presentment based on the information presented to them whether it is more likely than not that
a material breach has occurred. In the event that the Committee unanimously determines that
it is more likely than not that a material breach has occurred, or if Schuler and/or Bryson
should believe that Elan has materially breached any obligation after the date hereof, then
the aggrieved party shall present the matter to an independent United States Mediator (to be
agreed within 10 days of the date hereof) who shall hear the parties and determine, based on
the information presented to him, within 72 hours of presentment, whether it is more likely
than not that a material breach has occurred. If such Mediator determines that it is more
likely than not that a material breach has occurred, then the aggrieved party shall be
permitted to present its grievance to the Irish High Court for determination. Should such
Mediator be unwilling or unable to make the aforesaid determination as to whether a material
breach has occurred, then the parties shall select an independent United States Mediator to
replace him, and failing agreement as to a replacement within 14 days then either party will
be able to invite the American Arbitration Association to nominate a substitute independent
United States Mediator. No grievance shall be presented and no claims or litigation shall be
filed in any forum other than the Irish High Court (save for claims arising under the
Confidentiality Agreement). All fees and expenses of such United States Mediator shall be
shared equally by the Parties unless otherwise determined by the Mediator. In no circumstances
will Schuler and Bryson be liable for legal expenses incurred by Elan prior to the date of
this agreement.

 

 

	6.	 	A memorandum of discontinuance will be filed on behalf of Elan in the Litigation on or before
January 1, 2012 and the parties agree that those proceedings should be dismissed with
prejudice unless, prior to that date, and having first followed the procedure set out in
clause 5 hereof, Elan has issued new proceedings in respect of a material breach by Schuler
and/or Bryson occurring after the date of this agreement, and coincident with dismissal the
Parties shall exchange appropriate mutual general releases (the form of which will be
negotiated within 10 days of the date hereof).

	7.	 	This Memorandum of Undertaking and any further or related agreements of the Parties shall be
legally binding and governed by Irish law and subject to the exclusive jurisdiction of the
Irish Courts.

	 	 	 

	/s/ Jack Schuler
 

	 	 
	Jack Schuler
	 	 
	 
	 	 
	/s/ Vaughn Bryson
 

	 	 
	Vaughn Bryson
	 	 
	 
	 	 
	/s/ Kelly Martin
 

	 	 
	Elan Corporation, plc

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]